NCT06827613
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06827613
Title A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors (START-002)
Acronym START-002
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Marengo Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
USC Norris Comprehensive Cancer Center RECRUITING Los Angeles California 90033 United States Details
UCLA Health RECRUITING Los Angeles California 90095 United States Details
Massachusetts General Hospital Cancer Center RECRUITING Boston Massachusetts 02114 United States Details
Ohio State University Comprehensive Cancer Center RECRUITING Columbus Ohio 43212 United States Details
Sarah Cannon Research Institute RECRUITING Nashville Tennessee 37203 United States Details
UT Health San Antonio MD Anderson Cancer Center RECRUITING San Antonio Texas 78229 United States Details
BC Cancer RECRUITING Vancouver British Columbia V5Z 1K1 Canada Details
Princess Margaret Cancer Centre RECRUITING Toronto Ontario M5G 2C4 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field